Adverse Drug Reactions Affiliated with Atypical Antipsychotics in Patients with Schizophrenia (original) (raw)

Pharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders

Noosha Niv

CNS Drugs, 2008

View PDFchevron_right

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

Jiří Horáček

CNS Drugs, 2006

View PDFchevron_right

Risk of Psychotropic Drug Interactions in Real World Settings: a Pilot Study in Patients with Schizophrenia and Schizoaffective Disorder

Melike Ceyhan Balcı Sengul

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 2014

View PDFchevron_right

Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs

Pere Cervera

Drug Safety, 2009

View PDFchevron_right

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East

Nasser Al Zain

Neuropsychiatric Disease and Treatment, 2015

View PDFchevron_right

Antipsychotic prescription trends according to ethnicity

Aqeel Hashmi

Psychiatric Bulletin, 2009

View PDFchevron_right

ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder

Jason Noel

American Journal of Health-system Pharmacy, 2020

View PDFchevron_right

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Omeiza Beida

South African journal of psychiatry, 2024

View PDFchevron_right

Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults

Lissette Saavedra

2012

View PDFchevron_right

Pharmacology of “atypicality” of antipsychotic drugs: status and perspectives

Adrian Newman-Tancredi

Archives of Psychiatry and …, 2010

View PDFchevron_right

Pharmacist-Designed and -Implemented Pharmaceutical Care Plan for Antipsychotic-Induced Movement Disorders

Cynthia Farrar

Pharmacotherapy, 2000

View PDFchevron_right

Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia

Alison Markwick

Schizophrenia Bulletin, 2005

View PDFchevron_right

Novel Antipsychotics and Severe Hyperlipidemia

Serge Beaulieu

Journal of Clinical Psychopharmacology, 2001

View PDFchevron_right

Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia

Giovambattista Sarro

Journal of Clinical Psychopharmacology, 2014

View PDFchevron_right

Effectiveness of clozapine in treatment-resistant schizophrenia

Raguraman Janakiraman

Indian Journal of Psychiatry, 2005

View PDFchevron_right

Resurgence of Long-Acting Antipsychotic Formulations

Steven Siegel

Current Psychiatry Reports, 2010

View PDFchevron_right

Metabolic Issues in Schizophrenic Patients Receiving Antipsychotic Treatment

PRAVEEN SHARMA

Indian Journal of Clinical Biochemistry, 2014

View PDFchevron_right

Long-term metabolic and inflammatory effects of second-generation antipsychotics: A study in mentally disordered offenders

Emilia Vassilopoulou

Public Health and Toxicology, 2022

View PDFchevron_right

Psychotropic Medications in the Elderly

Jason Strauss

Manual of Geriatric Anesthesia, 2012

View PDFchevron_right

Real World" Atypical Antipsychotic Prescribing Practices in Public Child and Adolescent Inpatient Settings

Peter Jensen

Schizophrenia Bulletin, 2002

View PDFchevron_right

On the Mechanism of Action of Antipsychotic Drugs: A Chemical Reaction Not Receptor Blockade

Christine Miller

Current Drug Discovery Technologies, 2013

View PDFchevron_right

A systematic review of pharmacogenetic testing to guide antipsychotic treatment

Georgie Hudson

Nature mental health, 2024

View PDFchevron_right

Cariprazine in the treatment of schizophrenia

Robert Litman

International Clinical Psychopharmacology, 2016

View PDFchevron_right

Pharmaceutical care in a long-stay psychiatric hospital

Ivana Ilickovic

European Journal of Hospital Pharmacy, 2015

View PDFchevron_right

Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK

Romà Adroer

BMJ Open, 2015

View PDFchevron_right